VIR Overview

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. It also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Its key product candidates include Elebsiran (VIR-2218); Tobevibart (VIR-3434); VIR-5818; VIR-5525, and VIR-5500. These molecules leverage the PRO-XTEN masking technology with TCEs targeting CD3 on T-cells and HER2, PSMA and EGFR, respectively, on tumor cells. Elebsiran is an investigational hepatitis B virus (HBV)-targeted small interfering RNA that reduces hepatitis B surface antigen (HBsAg). Tobevibart is an investigational neutralizing monoclonal antibody that has been engineered for immune engagement and targets a conserved region on the HBsAg.

Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is15.60 USD with a low forecast of 12.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vir Biotechnology Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Vir Biotechnology Inc. EPS for the last quarter amounts to -0.85 USD, decreased -3.41

Vir Biotechnology Inc (VIR) has 367 emplpoyees as of June 21 2026.

Today VIR has the market capitalization of 1.54B USD.